Functional Cellular Anti-Tumor Mechanisms are Augmented by Genetic Proteoglycan Targeting. by Gupta, Purva et al.
UC San Diego
UC San Diego Previously Published Works
Title
Functional Cellular Anti-Tumor Mechanisms are Augmented by Genetic Proteoglycan 
Targeting.
Permalink
https://escholarship.org/uc/item/3rq1s669
Journal
Neoplasia (New York, N.Y.), 22(2)
ISSN
1522-8002
Authors
Gupta, Purva
Johns, Scott C
Kim, So Young
et al.
Publication Date
2019-12-30
DOI
10.1016/j.neo.2019.11.003
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume 22 Number 2 February 2020 pp. 86–97Original ResearchAbbrevi
Dendri
Lewis l
Major
valbum
T cell r
⇑ Add
System
3350 L
e-mail aFunctional Cellular Anti-Tumor
Mechanisms are Augmented
by Genetic Proteoglycan Targetingis
lic
ht
ations: BMDCs, Bone marrow dendritic cells, CD11c, CD11c locus, DC,
tic cell, HS, Heparan sulfate, HSPG, Heparan sulfate proteoglycan, LLC,
ung carcinoma, LPS, Lipopolysaccharide, LysM, M Lysozyme locus, MHC,
histocompatibility complex, Ndst, N-deacetylase/N-sulfotransferase, Ova, O-
in, Sdc, Syndecan, SIINFEKL, Ova peptide sequence for Ova257 Ova264, TcR,
eceptor, TIL, Tumor Infiltrating Lymphocyte, Treg, Regulatory T cell
ress all correspondence to: Mark M. Fuster, MD, VA San Diego Healthcare
and UCSD Department of Medicine, Division of Pulmonary & Critical Care,
a Jolla Village Drive, San Diego, CA 92161-111J, United States.
ddress: mfuster@ucsd.edu (M.M. Fuster), mfuster@ucsd.edu (M.M. Fuster).Purva Gupta a,b; Scott C. Johns a,b; So Young Kim a,b;
Roland El Ghazal b; Elina I. Zuniga c; Mark M.
Fuster a,b,d,⇑
a VA San Diego Healthcare System, Medical and Research Sections, La Jolla, CA 92161, United
States; b Department of Medicine, Division of Pulmonary and Critical Care, University of
California San Diego, La Jolla, CA 92037, United States; c Division of Biological Sciences,
United States; d Glycobiology Research and Training Center, University of California
San Diego, La Jolla, CA 92093, United StatesAbstract
While recent research points to the importance of glycans in cancer immunity, knowledge on functional mechanisms is lacking. In
lung carcinoma among other tumors, anti-tumor immunity is suppressed; and while some recent therapies boost T-cell mediated
immunity by targeting immune-checkpoint pathways, robust responses are uncommon. Augmenting tumor antigen-specific
immune responses by endogenous dendritic cells (DCs) is appealing from a specificity standpoint, but challenging. Here, we show
that restricting a heparan sulfate (HS) loss-of-function mutation in the HS sulfating enzyme Ndst1 to predominantly conventional
DCs (Ndst1f/f CD11cCre+ mutation) results in marked inhibition of Lewis lung carcinoma growth along with increased tumor-
associated CD8+ T cells. In mice deficient in a major DC HS proteoglycan (syndecan-4), splenic CD8+ T cells showed increased
anti-tumor cytotoxic responses relative to controls. Studies examining Ndst1f/f CD11cCre + mutants revealed that mutation was
associated with an increase in anti-tumor cytolysis using either splenic CD8+ T cells or tumor-infiltrating (TIL) CD8+ T cells puri-
fied ex-vivo, and tested in pooled effector-to-target cytolytic assays against tumor cells from respective animals. On glycan compo-
sitional analysis, HS purified from Ndst1f/f CD11cCre + mutant DCs had reduced overall sulfation, including reduced sulfation of a
tri-sulfated disaccharide species that was intriguingly abundant on wildtype DC HS. Interestingly, antigen presentation in the con-
text of major histocompatibility complex class-I (MHC-I) was enhanced in mutant DCs, with more striking effects in the setting of
HS under-sulfation, pointing to a likely regulatory role by sulfated glycans at the antigen/MHC-I – T-cell interface; and possibly
future opportunities to improve antigen-specific T cell responses by immunologic targeting of HS proteoglycans in cancer.Neoplasia (2019) xx xxx–xxxIntroduction
In cancer, dendritic cells (DCs) are typically subverted and inefficient
in their classic functions as both professional antigen presenting cells and
mediators of innate and adaptive immunity against novel (pathogen and/
or tumor) stimuli. Classical DCs are able to respond to both immunostim-
ulatory signals such as granulocyte–macrophage colony stimulatory factor
(GM-CSF), interleukin-1 (IL-1), or interferon-gamma (IFNc) [1–3], and
pathogen associated toll-like receptor (TLR) signals (e.g., lipopolysaccha-
ride (LPS), poly-IC or CpG motifs) [4] in a manner that promotes both 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
enses/by-nc-nd/4.0/).
tps://doi.org/10.1016/j.neo.2019.11.003
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clearance functions. The latter include increased performance in cross-
presentation of antigen to T cells [5]. These responses are inhibited by a
variety of immunosuppressive stimuli, including suppressive cytokines
such as transforming growth factor-beta (TGF-b) and interleukin-10
(IL-10) or the presence of T-regulatory cells in the tumor microenviron-
ment [3,6,7]. Moreover, while a variety of agents have been found to mod-
ulate co-stimulatory or co-inhibitory signals during DC – T cell
interactions, improving the quality of the ``epicenter'' interaction between
DC-presented antigen in the context of MHC and the T cell receptor
remains an area of challenge and opportunity [8,9]. Harnessing this inter-
action positively may allow one to boost both the magnitude and the
specificity of antigen-driven anti-tumor responses, and minimize non-
specific immunologic activation and autoimmune side-effects during
immunotherapy [10].
Previously, we had shown that reducing the sulfation of unique com-
plex carbohydrates (specifically heparan sulfate) expressed by the lym-
phatic endothelium may affect chemokine-dependent trafficking of DCs
toward lymphatic monolayers [11]. At the same time, we also questioned
the immunologic effects of targeting glycans on the trafficking DC effector
cells, with special interests in T cell responses and antigen presentation.
Preliminary findings from targeting endogenous glycosaminoglycans on
DCs revealed a slowing of lymphatic chemokine-driven DC trafficking,
implying a role for DC cell-surface HS in DC migration kinetics; and pro-
motion of DC maturation was also noted [12]. Moreover, moderate inhi-
bition of tumor growth in mice was observed when genetic HS targeting
was directed to myeloid-derived monocytes, consisting of DCs enriched in
a mixture of macrophages and granulocytes that were likely targeted to
some extent as well. While DCs purified from such tumors showed
increased maturation, the myeloid mutation remained somewhat non-
specific; and the functional effects of such genetic glycan alterations on
DC glycan composition, anti-tumor DC-mediated immune functions
(including CD8+ T cell proliferation and MHC associated antigen presen-
tation) remain undiscovered.
In this work, we have restricted Ndst1 mutation to CD11c+ cells
in vivo to thereby achieve reduced sulfation of HS in predominantly con-
ventional lymphoid-resident and migratory DCs (cDCs and mDCs)
[13,14]. We herein demonstrate that driving such a mutation in this fam-
ily of DCs results in a relatively more dramatic inhibitory effect on exper-
imental tumor growth. Additionally, using a Lewis lung carcinoma model,
we investigate and report the functional consequences of HS mutation on
mechanisms of anti-tumor immunity, examining how under-sulfated HS
on the DC surface results in improved ex-vivo CD8+ T cell mediated
tumor cytolysis and boosts MHC-I associated antigen-presenting capacity.
Moreover, similar outcomes are demonstrated in the setting of a loss-of-
function mutation in a major DC-associated HS proteoglycan,
syndecan-4. These insights on the increased magnitude of anti-tumor
effects (with greater DC mutation specificity in vivo) paired with the func-
tional importance of under-sulfated DC HS on antigen presentation and
augmented functional CD8+ T cell anti-tumor immunity highlight novel
biological mechanisms as well as a basis for therapeutic development.Methods
Cell Lines and Cell Culture
Lewis Lung Carcinoma Cells (LL/2; ATCC) were cultured in DMEM
Hi-glucose with 10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin. Cells were harvested using Accutase (Corning) after 5 min incuba-
tion and cell counting after neutralization. Primary cells in other studies
included isolated tumor cells from subcutaneous tumors; CD8+ T cells
from spleens or tumors; and DCs from bone marrow as described.Primary Cell Preparations
All CD8+ T cells were prepared fresh. Spleen CD8+ T cells were pre-
pared through mechanical spleen dissociation and passage through 40 mm
filters followed by magnetic-column negative selection according to man-
ufacturer instructions (Dynabeads Untouched CD8; Invitrogen). Tumor
cells for cytolytic assays were prepared from subcutaneous tumors as fol-
lows: At day 14 following LLC subcutaneous inoculation, tumors were
dissected from euthanized mice, rinsed with PBS, minced with a razor
in a small petri-dish, and 5 ml of 0.2% Collagenase (Sigma) and 15 mg/
ml DNase I (Sigma) solution was added, with digestion at 37 C on a
rotating platform for 1 h. Single-cell suspensions were obtained by filtering
digests through 100 mm filters. Magnetic bead separation of tumor cells
was performed through negative selection according to the tumor cell iso-
lation kit manufacturer (Miltenyi, 130–110-187). For CD8+ T cells from
tumors (TILs), filtered tumor digests were washed in labeling buffer (0.5%
BSA, 2 mM EDTA in PBS), with the cell pellet resuspended to a concen-
tration of 1.0  107 cells/ml, and incubated in 5 lg/ml biotinylated anti-
CD8+ antibody (Life Technologies) at 4 C for 1 h. Subsequent labeling
with magnetic anti-biotin microbeads and positive selection was carried
out according to the manufacturer (Miltenyi). Bone marrow dendritic cells
(BMDCs) were prepared from femurs dissected from freshly euthanized
mice using sterile technique: Marrow was washed from femurs using a
25 gauge needle/syringe with ice-cold serum free RPMI-1640 (Gibco) into
a 15 ml conical tube. Cells were resuspended in DC growth medium
[RPMI-1640 supplemented with penicillin/streptomycin (100 U/ml and
100 lg/ml, respectively; Sigma), L-glutamine (2 mM; Corning), beta-
mercaptoethanol (55 lM; Gibco), 10% heat-inactivated FBS,
1 mM nonessential amino acids (Invitrogen), 10 mM HEPES (Affyme-
trix), and 20 ng/ml GM-CSF (Peprotech). Differentiation over 10 days
was performed with media changes every 3 days.Genetic Mouse Models
For targeting HS N-sulfation in conventional DCs, the Cd11c trans-
genic strain (B6.Cg-Tg(Itgax-cre)1-1Reiz/J #008068 JaxMice) [13] was
crossed extensively onto mice with a conditional mutation in N-deacety
lase/N-sulfotransferase-1 (Ndst1 f/f) previously backcrossed onto
C57Bl/6. This yielded Ndst1f/f CD11cCre + mutants, wherein Cre-
mediated deletion of a loxP flanked segment of the Ndst1 Exon-2 coding
region was achieved under control of the CD11c integrin prompter/
enhancer; with Ndst1f/f CD11cCre littermates used as wildtype controls.
For the Ndst1f/f LysMCre mutant line, targeting Ndst1 mutation to the
myeloid lineage, mice were generated and maintained as previously pub-
lished [12]. Syndecan4 knockout mice (Sdc4/) bear a constitutional
deficiency in the HS proteoglycan syndecan-4 [15], and were originally
a kind gift from Dr. Paul Goetinck. They were backcrossed onto
C57Bl/6. The reduction in Sdc4 expression in homozygous null mutants
has previously been shown to be >99% by qPCR [12].Mouse Tumors and Models
LLC cells were injected (5.0x105 cells in 100 ll serum-free DMEM)
subcutaneously into the hindquarter of isoflorane-anesthetized mice.
Tumors in Ndst1f/f LysMCre mutants and Sdc4 mutants were grown
simultaneously over 20 days with close observation and monitoring
according to approved protocols, and mice euthanized using carbon diox-
ide according to American Veterinary Medical Association guidelines.
Tumors were grown on the Ndst1f/f CD11cCre mutant background under
similar conditions and observation protocol (over 14 d period). Tumors
were extracted and handled in sterile manner; and measured by calipers
with volume based on ellipsoid method [0.5  length  (width)2]. Cell
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preparations). For intra-tracheal short-term tumor establishment,
culture-harvested LLC cells were instilled (1.0  106 cells in 100 ml
PBS) by intra-tracheal intubation into isoflorane-anaesthetized mice using
methods as published [16]. Mice were sacrificed after 1 week; and
bronchiolar-alveolar lavage (BAL) fluid was collected by suture-securing
a blunt-ended 19 gauge needle cannulated into the trachea with 1.5 ml
total PBS injected (in three 0.5 ml BAL washes). Animal studies were
approved by the local institutional animal-care-and-use-committee
(IACUC).
Dendritic Cell Preparations from Tissues
Following tissue digests, magnetic separation of DCs (CD11c + cells)
was carried out per manufacturer instructions: Cells were labeled with
CD11c microBeads (Miltenyi), loaded onto MACS MS magnetic bead
columns, and separated using a magnetic separator (Miltenyi MiniMACS)
according to manufacturer protocol to collect CD11c+ cell populations.
Quantitative PCR (as described separately) was used to assess Ndst1
expression in positively selected cells.
Flow Cytometry
Dendritic Cell Maturation Assessments
For maturation markers, cells were labeled in 2 lg/ml of PE-labeled
anti-CD86 antibody (Biolegend, 105007) and 2 lg/ml APC-labeled
anti-MHC-II antibody (Life Technologies, 17–5321) for 1 h on ice;
and following washing, acquisition was carried out on a Beckman Coulter
Cytoflex cytometer. As a maturation control, Ndst1f/f CD11cCre+ and
Cre DCs were incubated with or without 1 mg/ml O55:B5 lipopolysac-
charide (LPS) for 6 h at 37 C. The cells were allowed to mature overnight
prior to labeling for flow cytometry. CD8+ T cell analyses: Purified CD8+
T cells from spleen or tumor were analyzed for purity by labeling with
2 lg/ml of anti-mouse CD8a PE (Tonbo, 50–0081) followed by incuba-
tion for 1 h on ice. Unlabeled cells and isotype-matched secondary anti-
body were used as controls; with flow cytometry to determine %CD8+
T cells. DC antigen presentation: For model-antigen loading, SIINFEKL
Ova peptide at 30 mM was incubated for 2 h with cells for each genotype.
Washed cells were then incubated with CD16/32 (FC block) in FACS
buffer, and resuspended in 100 ml flow buffer with either 2 lg/ml of
anti-mouse SIINFEKL/H-2 Kb APC (mAb 25-D1.16; Life Technologies,
17-5743-80), isotype control antibody, or non-antibody containing med-
ium; and labeling for 1 h on ice. (Antibody clone 25-D1.16 specifically
detects SIINFEKL peptide in the context of MHC-I.) Washed cells were
analyzed on the cytometer, with relative histogram shift in mean fluores-
cence intensity (MFI) as compared to control used to quantify level of
antigen/MHC-I presentation for any given sample. Analysis of data was
carried out using FlowJo (V X.0.7).
BAL CD8+ T-Cell Analysis
Initial net BAL cell concentration was determined; and FC-block was
carried out for 15 min, and 2 lg/ml of anti-mouse CD8a PE (Tonobo,
50–0081) was incubated with cells for 1 h on ice. Unlabeled cells and
isotype-match secondary antibody were used as controls; and flow cytom-
etry was used to determine %CD8+ T cells in the total BAL population.
Cytolysis Assays and Cell Preparations
LLC cells isolated from subcutaneous tumors in Ndst1f/f CD11cCre+
mutant and Cre control mice were mixed with CD8+ T-cells from
spleens or tumors (at 10:1 and 20:1 CD8+ T cell to tumor cell Effec-tor:Target ratios) following appropriate dilutions of cells from primary-
cell preparations as described separately. Most experiments involved
1.0  105 CD8+ T cells mixed with 5.0  103 LLC tumor cells (i.e.,
for 20:1 ratio) in a final volume of 100 ml of DMEM medium. Cells were
plated in triplicate for each experimental sample on a V-bottom 96-well
plate. A media control was added for each experiment as background.
The plate was incubated overnight at 37 C to allow for cytolysis, and
cytotoxicity was assayed using the CytoTox-Glo (Promega) kit according
to manufacturer recommendations. Luminescence was read on a DTX
Multimode Detector (Beckman Coulter) to detect luminescent protease-
leak cytoxicity signals.Real time Quantitative PCR (qPCR)
Total RNA was purified from cells with a RNAqueous 4-PCR kit
(Ambion); and a SuperScript III kit (Invitrogen) was used to reverse-
transcribe cDNA according to manufacturer instructions. Real-time
PCR was carried out using an iQ Sybr Green Supermix Kit (BioRad) with
100 ng cDNA: Primer sequences (50–30) were as follows:
Ndst1 (forward 50-GGACATCTGGTCTAAG-30; reverse 50-GATG
CCTTTGTGATAG-30),
Sdc1 (forward 50-GGAGCAGGACTTCACCTTTG-30; reverse 50-T
ACAGCATGAAACCCACCAG-30),
Sdc2 (forward 50-GCTGCTCCAAAAGTGGAAAC-30; reverse 50-C
AGCAATGACAGCTGCTAGG-30),
Sdc3 (forward 50-GAGCCTGACATCCCTGAGAG-30; reverse 50-C
CCACAGCTACCACCTCATT-30),
Sdc4 (forward 50-GAGCCCTACCAGACGATGAG-30; reverse 50-C
AGTGCTGGACATTGACACC-30).
PCR cycle conditions were as follows: 95 C for 3 min followed by 40
cycles of 95 C for 15 s, 59 C for 45 s, and 72 C for 45 s. Relative
expression of a target gene was normalized against expression level of
GAPDH or beta-Actin as indicated using the 2DDCt method with ulti-
mate expression as target mRNA as a percentage of GAPDH or beta-
Actin expression [17].Glycan Compositional Analysis
Purification of HS from BMDCs was carried out using HS preparation
methods as previously described [18]. Cells were harvested from 10-day
GM-CSF based DC differentiation cultures of marrow from the femurs
of Ndst1f/f CD11cCre+ versus Cre control mice as described for BMDC
Primary Cell Preparations, above. Briefly, following glycan de-
polymerization with heparin lyases overnight, disaccharide analysis was
carried out using quantitative liquid chromatography/mass spectrometry
(LC/MS) [19]: After drying samples down, aniline labeling of disaccharide
reducing ends was carried out (in 15 ll of 1 M NaCNBH3 and [
12C6]ani-
line freshly prepared in dimethyl sulfoxide/acetic acid (7:3, v/v) for 16 h at
37 C) with products dried down. Using a C18 reversed phase column
(0.21  15 cm; Thermo), derivatized disaccharides were separated with
ion pairing agent (dibutylamine, Sigma) [20], and eluted ions of interest
were monitored in negative ion mode on a mass spectrometer (LTQ Orbi-
trap, Thermo-Finnigan; capillary temp 150 C; spray voltage 4.0 kV).
Extracted ion current data were analyzed with Qual Browser software
(Thermo-Finnigan). Quantitative composition analysis of disaccharides
was performed by comparison with known amounts of differentially
labeled standard [13C6]aniline added to the sample before LC/MS.
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Culture-differentiated DCs were exposed to O55:B5 LPS at 0.1 lg/ml
for various time points. Cells were collected and centrifuged to pellets that
were lysed in 100 ml 1X RIPA buffer (Teknova) supplemented with 1 mM
Sodium orthovanadate, 1 mM PMSF and 10 ml/ml protease inhibitor
cocktail and stored at 20 C. Protein was quantified from thawed sam-
ples using a Micro BCA protein assay kit according to manufacturer pro-
tocol (Thermo) and Spectramax 190 microplate reader with
concentrations calculated for equal loading. Samples were loaded onto a
pre-cast 4%-15% gel (BIO-RAD) with a Precision Plus Protein Kaleido-
scope ladder (BIO-RAD) and run at 180 V for 30 min in 1X Tris/Gly-
cine/SDS buffer (BIO-RAD). Protein was transferred onto 0.2 mm
Nitrocellulose filter paper sandwiches (BIO-RAD) in transfer buffer
(100 mM CAPS and 20% methanol) at 30 V for 2 h in the cold. For
phospho-NF-kB p65 subunit labeling, membranes were rinsed with 1X
Tween-20/Tris-buffer saline (TTBS), and blocked for 1 h in Odyssey
Blocking buffer (LI-COR). Phospho NF-kB p65 antibody (Cell Signaling,
3031 s) diluted in blocking buffer (1:1000) was incubated on the mem-
brane at 4 C on a shaker overnight. Membranes were washed 4X with
1X TTBS for 15 min; and IRDye 800CW goat anti-rabbit IgG secondary
antibody diluted in blocking buffer (1:10,000) was used to incubate the
membrane for 1 h at room temp in the dark, on a shaker. Washed mem-
branes were air dried in the dark and scanned (LI-COR Odyssey) to detect
bands with intensities calculated using Odyssey software.
Statistics
Mean values (þSD) were obtained for absolute and normalized tumor
volumes, cytolysis determinations, tumor T-cell indices, BAL T cell per-
centages, and qPCR expression values. Comparisons of means were made
by Student's T-test with the difference considered significant at P < 0.05.
A one sample T-test was used for comparing changes in flow-cytometric
mean fluorescence intensity (MFI) representing antigen presentation by
mutant DCs (relative to normalized values of control DCs in individual
experiments).Results
Augmented Anti-Tumor DC Functions in Sdc4/ Mice, and a
Strategy to Enrich HS Targeting on DCs
We introduced glycan-targeted genetic models to examine roles of HS
in tumor immunity, with a combined evaluation of Lewis lung carcinoma
(LLC) tumor growth in two known models targeting HS on the DC cell
surface. This was with an eye to ex-vivo mechanistic analyses using HS-
deficient DCs. In first tumor models, we specifically employed published
mouse models wherein we originally had begun to characterize maturation
and trafficking properties of HS-deficient myelo-monocytic cells as well as
tumor immunophenotyping on HS-deficient genetic backgrounds [12]. In
extended tumor-growth studies in mice bearing (i) a myeloid-driven muta-
tion in Ndst1 (with under-sulfated HS chains on myeloid-derived mono-
cytes/DCs and some macrophages/granulocytes [21]) and (ii) a systemic
mutation in the HS proteoglycan core protein syndecan-4 (Sdc4) which
is strongly expressed on DCs [12], we found: Moderate (in Ndst1 mutant)
and more marked (in Sdc4 mutant) inhibition in tumor growth when the
two mutations were examined simultaneously (Figure 1A). For initial ex-
vivo mechanistic studies, given the magnitude of the tumor pheontype, we
chose to examine the effect of mutation on the cytolytic properties of CD8
+ splenocytes from tumor-bearing Sdc4/ mice against harvested tumor
cells from the respective mice. Mutation was associated with increased
CD8+ T-cell mediated tumor cytolysis (Figure 1B). Given these findingsand the importance of DC-mediated antigen presentation in the develop-
ment of specific cytotoxic T cell responses, and since mutation could the-
oretically affect functional properties of both DCs and T cells in Sdc4
mutants, we next examined whether Sdc4 deficiency specifically on DCs
purified from the mice might be associated with unique antigen presenta-
tion properties: Using an antibody that detects model antigen (Ova SIIN-
FEKL) on antigen-pulsed DCs in the context of MHC-I (anti-SIINFEKL/
H-2 Kb), and probing cultured bone marrow derived DCs (BMDCs)
from Sdc4/ mice versus wildtype controls with this antibody by flow
cytometry revealed that mutation is associated with a significant increase
in antigen presentation by the cultured DCs (Figure 1C).
Given the above findings and the possibility that HS deficiency (or
altering the fine structure of HS) on DCs might augment mechanisms that
boost anti-tumor cytolysis by CD8+ splenocytes at the end of a tumor
growth period, including antigen presentation, we sought to increase the
specificity of glycan targeting on DCs in vivo, while keeping robust repre-
sentation across conventional DC lines. With this strategy and focus (Fig-
ure 1D), we generated Ndst1f/f CD11cCre+ (and Cre floxed wild-type
control littermates), and assessed deletion efficiency in DCs isolated from
distinct tissues, including organ-level deletion (lungs) as well as tumor-
derived DCs (TIDCs) (Figure 1E). Since CD11c may be expressed to
some extent in macrophages, we assessed BMDCs (used in several exper-
iments herein) for presence of F4/80+ macrophages by flow cytometry
(Figure 1F), wherein day-10 (standard differentiation period) GM-CSF
differentiated cells from culture demonstrated up to 70% CD11c+ cells,
with under 20% macrophages (CD11c+ F4/80+ cells) at time of harvest.
This marrow preparation is thus enriched with a robust DC population for
in vitro studies used herein for mechanistic studies using primary gene-
targeted DCs. Upon establishing this new and more specific targeting
strategy, we additionally examined how Ndst1 mutation in the cultured
primary DCs would affect syndecan-4 (or another syndecan) core protein
expression in Ndst1 mutant (Cre+) and wildtype control (Cre-) DCs from
culture, and found no significant up-regulation of the two dominant syn-
decan core proteins (Sdc3 and Sdc4) expressed by Ndst1f/f CD11cCre+
mutant DCs (Figure 1G). While Sdc1 appeared to be up-regulated in
mutant cells, it was minimally expressed to begin with; and thus, mutation
in DC Ndst1 does not appear to lead to major HS chain up-regulation by
key transmembrane (syndecan) HSPG species.Tumor Phenotype of a CD11c Driven Mutation in HS Biosynthesis
Growth of LLC tumors in Ndst1f/f CD11cCre+ mutants was markedly
inhibited in comparison to that in floxed Cre littermates (Figure 2A).
Interestingly, the magnitude of experimental tumor inhibition on the
Ndst1f/f CD11cCre+ background is considerably greater than that which
we found in tumor models in Ndst1f/f LysMCre+ mutant mice (where
mutation was targeted broadly to myeloid cells including DCs (with cul-
ture enrichment), macrophages and granulocytes [13,21], as in prior work
[12]. Restricting mutation of Ndst1 to the CD11c+ subset of monocytes
(using CD11cCre) allows for more specific and robust enrichment of this
mutation to a predominantly classic DC population [13,14]. This is also
despite the fact that Ndst1 deletion efficiency in tumor DCs isolated from
the CD11cCre transgenic background (50% reduction by qPCR; Fig-
ure 1E), if anything, is modestly lower than that achieved in LysMCre
mutant cells (70–80% reduction by qPCR) [12].
Beyond implying the unique importance of HS under-sulfation in this
specific myeloid subset of monocytes in anti-tumor immunity (Cre expres-
sion in classic DCs > plasmacytoid DCs in this model [13]), we also find
important in vivo effects of this mutation on tumor-associated CD8+ T
cells. In particular, in addition to an increase in harvested CD8+ T cells
from subcutaneous tumors on the Ndst1f/f/CD11cCre+ background as
compared to that of Cre controls (Figure 2B); in a model of airway-
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bronchoalveolar lavage (BAL) of Ndst1f/f CD11c+ mutants as compared
to that of Cre controls (Figure 2D). This model was used to probe
tumor-induced T cell proliferation in the lung through a relatively
short-exposure model aimed to elicit an early cellular anti-tumor immune
response in the lung as an orthotopic ``home'' for LLCs, and wherein
lung-DC dependent T cell responses could be measured. More generally,
the ability of DC Ndst1 mutation to stimulate T cells in these experimen-tal tumor assays demonstrates that DCs with under-sulfated HS appear to
have augmented ability to stimulate T cell proliferation in vivo.
CD11cCre Driven Ndst1 Mutation: Analysis of HS Composition and
Augmented DC Maturation
Isolation of a relatively large load of DCs from the pooled marrows of
Ndst1 f/f CD11cCre+ mutant versus Cre wildtype mice (differentiated
Figure 1. Anti-tumor cellular immunity is increased in syndecan-4 deficient mice, and introduction of a genetic model to target glycan sulfation with
optimum DC specificity. (A) Tumor growth of Lewis lung carcinomas (LLC) in the hindquarter of Sdc4/ mice, Ndst1f/f LysMCre+ mutant mice
bearing a myeloid-driven mutation in the major HS sulfating enzyme Ndst1, and Cre wildtype (WT) controls was assessed at 20 days following
subcutaneous inoculation of tumor cells in the hindquarter. Tumor volumes are graphed (*P = 0.05 for difference in mean with WT; **P < 0.01 for
difference in mean with WT). In separate anti-tumor cytolysis studies (B), we examined a model wherein ex-vivo CD8+ T-lymphocytes harvested from
the spleen of a LLC tumor-bearing mouse are combined with tumor cells purified from a whole-tumor cell digest from the same mouse, and examined for
cytolysis using a dead-cell protease release assay after overnight incubation at a 20:1 T-cell/Tumor-cell effector/target ratio. Graph shows the mean degree
of anti-tumor cytolysis achieved by CD8+ T cells from n = 6 Sdc4/ mice normalized to that of n = 5 WT C57Bl/6 control mice (**P < 0.01 for
difference). (C) Cultured bone marrow derived DCs from Sdc4/ mutant and WT control mice were exposed to Ova SIINFEKL peptide, and
examined for peptide presentation by flow cytometry using antibody that binds specifically to SIINFEKL in context of MHC-I. Graph shows-fold
presentation of peptide-pulsed cells normalized to that of no-peptide controls run in parallel (*P = 0.02 for difference). (D) Schematic introducing
strategy to optimally target the sulfation fine structure of HS glycan chains on predominantly conventional DCs. Cartoon at center shows HS polymers
tethered to HSPG core protein (i.e., syndecan-4 on membrane) through O-linkage to xylose, and with wildtype HS chain oriented to left of core protein
modified by clustered sulfate domains initiated by the action of Ndst: NS, 2S, 6S, and 3S sulfate groups, where Ndst mediates NS modifications on
glucosamine residues (red arrows). N-sulfation modification on a chemical HS disaccharide (uronic-acid and glucosamine residues) is shown to left (where
-R1 and/or -R2 may be substituted with -H and/or -SO3
. Mice with a conditional mutation in Ndst1 are crossed with CD11cCre transgenic mutants
(box illustrates floxed/LoxP targets for Cre, arrows, in exon 2 of Ndst1 gene) to target HS under-sulfation to DCs, (illustrated by under-sulfated HS
chains oriented to right). (E) Reduced expression of Ndst1 (qPCR, relative to GAPDH) in mutant DCs purified from lung (left histogram; from lungs of
n = 3 mice per genotype; *P = 0.03 for difference) and in DCs purified from LLC tumors (right; from tumors of n = 4 mice per genotype; **P < 0.01 for
difference). (F) Flow cytometry of cultured marrow-derived mutant and control DCs showing CD11c+ F4/80-DC populations and CD11c+ F4/80+
macrophage populations (13% and 16% of cells in these preparations). (G) Expression of syndecan HSPG core proteins and the secreted HSPG perlecan
(as %GAPDH) in DCs from Ndst1f/f CD11cCre+ mutant and Cre control mice (*P = 0.02 for Sdc1 expression difference, **P < 0.01 for Sdc2
difference; *P = 0.01 for Sdc4 difference).
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in vitro functional studies) was required for simultaneous analyses of quan-
titative glycan sulfation and a confirmatory DC functional effect on mat-
uration markers on the same cells. Glycosaminoglycan structural analysis
of HS purified from mutant and wildtype DCs, through quantitative liq-
uid chromatography/mass-spectrometry (LC/MS) of HS disaccharides
released by heparin-lyase digestion of the purified HS, shows marked
reductions in sulfation of HS disaccharides harvested from mutant DCs:
In particular, DC-mutant HS had marked reductions in N-sulfated disac-
charides, including mono (N-) sulfated and di-(2-O-, N-) (6-O-, N-) sul-
fated as well as more highly expressed unique tri-sulfated (N-, 2-O-, and 6-
O-sulfated) moiety (Figure 3B). The latter appeared to be more abundant
in relative quantity as a sulfated disaccharide species on DCs as compared,
for example, to another key host cell-type from the mesenchymal compart-
ment (e.g., lymphatic endothelium as analyzed in [23]). In addition, mat-
uration analysis of the same cells by flow cytometry confirmed that the
Ndst1 mutation in marrow-derived DCs was associated with a marked
increase in maturation markers, as assessed by the CD86/MHC-II dual-
positive subset (Figure 3C); and with a further increase, as might be
expected, following LPS stimulation as a known DC maturation stimulus.
Curiously, NF-kB activation appears to be important for DC maturation
[24]); and in pilot studies where we examined phosphorylation of the NF-
kB subunit p65 to LPS stimulation in the same cells, while activation of
control cells was somewhat variable, trends showed that for any given
phospho-p65 response to LPS in Ndst1f/f CD11cCre control DCs,
responses by Ndst1f/f CD11cCre+ mutant cells were greater (Supplemental
Figure 1).
The findings in studies on BMDCs are in the setting of a significant
Cre mediated reduction in Ndst1 expression in mutant marrow DCs (Fig-
ure 3A). The latter typically varied from 50% to 70% reductions in Ndst1
expression, whether examining CD11cCre mediated Ndst1 deletion effi-
ciency in marrow derived (BM)DCs or in DCs purified (using anti-
CD11c bead based methods) from the lung or LLC tumors (Figure 1E).
Nevertheless, the genetic deletion efficiency was sufficient to drive rela-
tively marked reductions in HS disaccharide sulfation (by LC/MS; Fig-
ure 3B) of HS disaccharides purified from GM-CSF differentiatedBMDCs from the marrow of Ndst1 f/f CD11cCre+ mutant mice. It should
be noted that while GM-CSF differentiated marrow cells consisted of a
major population of BMDCs, the degree to which a minor population
of CD11c negative cells may have ``diluted'' the effects of mutation
appears to be low, as the degree of reduction in the sulfation of HS from
the cultured cells by compositional analysis (mean of 64% sulfation per
HS disaccharide in HS from wildtype cells compared to mean of 37% sul-
fation per HS disaccharide from mutant cells; reported in Figure 3B
legend) is of a similar order of magnitude as that of the overall degree
of reduction in Ndst1 expression by quantitative PCR analysis (Figure 3A)
of mutant compared to wildtype cells from the same cultured preparations.
DC HS Under-Sulfation Augments Anti-Tumor CD8+ T Cell
Activity and DC Antigen/MHC-I Presentation
Following experimental tumor establishment in Ndst1f/f CD11cCre+
mutants and Cre littermates (as in Figure 2A), we functionally examined
CD8+ T cells from spleens of mutant versus wildtype mice for degree of
cytolytic anti-tumor responses, given both the tumor phenotype and
increased DC maturation. Incubating CD8+ T-splenocytes harvested
and pooled from tumor-bearing mice with LLC tumor cells purified
and pooled from the same mice in an overnight Effector-to-Target expo-
sure resulted in cytolytic responses that were augmented in the Ndst1f/f
CD11cCre+ mutant background (Figure 4A). The difference in cytolysis
relative to control was also greater at a higher CD8+ T-cell/Tumor-cell
effector/target ratio. Since the Ndst1f/f CD11cCre genetic model uniquely
targets DCs optimally, as a biologic proof-of-principle under these condi-
tions (where T cells are genetically un-altered), we examined whether CD8
+ T cells purified directly from the LLC tumors could exhibit similar aug-
mented anti-tumor cytolytic behavior in the setting of the Ndst1f/f
CD11cCre+ mutation; and indeed, this appeared to be the case
(Figure 4B).
Mechanistically, we considered whether greater CD8+ T cell mediated
cytolytic capacity in mutants (along with possibly greater DC maturation;
Figure 3C) might be associated with differences in antigen presenting
capacity by mutant DCs. Using BMDCs pulsed with the Ova peptide
Figure 2. Tumor growth inhibition in Ndst1f/f Cd11cCre mutant mice and effects on tumor associated CD8+ T cell proliferation. (A) The volumes of
LLC tumors grown in Ndst1f/f Cd11cCre+ mutants were compared to those of Ndst1f/f CD11cCre control mice, measured 14 days after injection of
LLC cells subcutaneously into the hindquarter. Scatter plot shows data from n = 15 controls versus n = 16 mutants normalized to the mean value for
controls (***P < 0.001 for difference). (B) The CD8+ T cell index (number of CD8+ T cells per lL tumor volume) is shown for whole tumor digests
from mutant versus wildtype control mice, showing mean indices for 6 separate experimental groups harvested from independent time periods; *P < 0.05
for difference. (C) Flow cytometric illustration of CD8+ T cells purified from tumor-digest purifications (using positive anti-CD8 bead selection method;
right histogram), and from spleen-digest extractions (negative selection method; left histogram). (D) Bronchoalveolar lavage (BAL) total cell counts (left
graph) and BAL CD8+ T cell counts (right graph) for BAL samples collected from n = 3 Ndst1f/f Cd11cCre+ mutants and n = 3 Cre control mice at
7 days following intratracheal inoculation of LLC tumor cells; *P < 0.05 for difference in means. (E) Expression of Ndst1 in DCs purified from cellular
whole-lung digests of mice in (D), expressed as %GAPDH; *P < 0.01 for difference in means.
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we found that DCs purified from Ndst1f/f CD11cCre+ mutants showed a
marked increase in MHC/peptide on the DC surface relative to Ndst1f/f
CD11cCre controls (Figure 4C). Interestingly, we demonstrate that
while Sdc4 deletion results in a modest though significant increase in anti-
gen presentation in SIINFEKL pulsed DCs (Figure 1C, showing 30%
increase in presentation among multiple Sdc4 mutant versus wildtype
DC replicates), targeting the HS glycan broadly through under-sulfation
(i.e., Ndst1f/f CD11cCre+ mutation) results in a markedly greater increase
in antigen presentation as a result of the HS-chain specific mutation (com-
paring normalized increases in means under the two mutations in Fig-
ure 4C). An example of augmented antigen presentation in Ndst1mutant DCs is shown in Figure 4D. Original data examining effects of
distinct (overnight versus 2 h) antigen pulsing periods for BMDCs using
cells from which glycan analysis was carried out (Figure 3B) confirmed
the effect of genotype on antigen presentation using those specific cells
(shown in Supplemental Figure 2).
Discussion
In this study, we examine how restriction of a glycan mutation to a
major subset of dendritic cells in vivo is sufficient to impact unique
dendritic-cell specific mechanisms that augment anti-tumor T cell
responses. By targeting mutation of a major HS sulfating enzyme (Ndst1)
Figure 3. Glycan targeting and compositional analysis of HS purified from Ndst1f/f targeted DCs. (A) Deletion efficiency of Ndst1 in day-10
differentiated cultured pooled BMDCs from Ndst1f/f CD11cCre+ versus Cre control mice (run in triplicate per genotype); *P = 0.02 for difference. (B)
Sulfation of HS disaccharides (released from total heparin lyase digestion of HS) purified from Ndst1f/f CD11cCre+ versus Cre control BMDCs was
determined by liquid chromatography/mass spectrometry and quantified as a percentage of total disaccharides. Detected disaccharide species on graph are
labeled below as unsulfated (68% for wildtype DCs versus 81% for mutant DCs) or as mono-, di-, and tri-sulfated species, with the latter being most
abundant among sulfated species. The family of N-sulfated species is indicated, with the majority of N-sulfation reduced in mutant DCs. In general,
Ndst1mutant HS also showed moderate reductions in 2-O and 6-O sulfation, which is consistent with the importance of Ndst1 in initiating HS sulfation
domains on HS chains during biosynthesis. Overall, the average SO3 (sulfation) per disaccharide for Ndst1 mutant HS was 37%, while the value for
wildtype HS was 64%. (C) Maturation marker testing of cultured BMDCs isolated from mutants and littermate controls (corresponding to BMDCs
shown in (B), differentiated in culture from pooled marrows of n = 3 mice per genotype). Cells were tested by flow cytometry for expression of standard
markers of DC maturation (CD86 and MHC-II) in the absence or presence of LPS stimulation. For each harvested population, the percentage of dual-
positive (CD86+/MHC-II+) cells is reported as the upper-right sub-population in dot plots corresponding to control versus mutant.
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gene (i.e., in Ndst1f/f CD11cCre+ mutants), we achieve under-sulfation of
HS in vivo predominantly in conventional lymphoid-resident and migra-
tory DCs (cDCs and mDCs) [13,14]. In association with a marked reduc-
tion in tumor growth on this mutant background, we find that the DC
glycan mutation is also sufficient to augment ex-vivo cytolytic anti-
tumor cell responses by CD8+ T-lymphocytes isolated from the spleens
of tumor-bearing mutants. A particularly interesting feature of the muta-
tion is that under-sulfation of HS on the DC surface appears to boost pre-
sentation of a DC molecular complex (antigen in the context of MHC-I)
at the ``center'' of the immune synapse that drives antigen-mediated anti-
tumor cytotoxic T cell responses. Similar anti-tumor DC-functional mat-
uration associated events, including MHC-I/antigen modulation, are
noted when we genetically reduce DC cell-surface HS through mutation
in a major DC cell-surface HS proteoglycan (i.e., syndecan 4). These find-ings, wherein targeting an alteration in the fine-structure of HS to a major
antigen-presenting DC subset results in augmented specific anti-tumor
mechanisms, provide a basis for improving endogenous DC-mediated
responses in cancer.
In prior studies we targeted mutation of Ndst1 to myelo-monocytic
cells [12], including DCs (but also some macrophages and neutrophils),
through a LysMCre transgenic approach. This resulted in a modest though
significant reduction in Lewis lung carcinoma (LLC) tumor growth; and
we repeated tumor assessments in parallel to that in Sdc4/ mutants
upon initiating the mechanistic work herein (Figure 1A) to pair with
our initial choice of mechanistic studies in Sdc4/ mice. The latter
mutation was associated with a somewhat more striking tumor growth
inhibition phenotype (Figure 1A, right bar): So with this mutation in
mind, we initially carried out a stringent functional anti-tumor immunity
challenge, examining how the Sdc4/mutation might impact the ability
Figure 4. Functional CD8+ tumor-cytotoxic immunity and DC model antigen presentation are augmented in Ndst1f/f CD11cCre mutants. (A) Ex-vivo
CD8+ T-lymphocytes harvested and pooled according to genotype from spleens of LLC tumor-bearing mice were combined with respective pooled
purified tumor cells isolated from the same mice, and examined for cytolysis using a dead-cell protease release assay after overnight incubation at 10:1 and
20:1 T-Cell/Tumor-cell effector/target ratios. Graph for each condition shows the mean degree of anti-tumor cytolysis achieved by Ndst1f/f CD11cCre+
mutant versus Ndst1f/f CD11cCre control CD8+ T cells normalized to that of controls; P = 0.07 for difference between means at 10:1 ratio; **P < 0.01
for difference at 20:1 ratio; **P < 0.01 for difference between wildtype controls at 10:1 versus 20:1. (B) Graph for cytolytic assays under 10:1 and 20:1
effector/target ratios using CD8+ T cells harvested directly from tumor digests as effector cells; *P = 0.01 for difference between means at 10:1 ratio;
***P < 0.001 for difference at 20:1 ratio; ***P < 0.001 for difference between wildtype controls at 10:1 versus 20:1. (C) Cultured bone marrow derived
DCs from Ndst1f/f CD11cCre+ mutant versus Ndst1f/f CD11cCre control mice were exposed to Ova SIINFEKL peptide, and examined for peptide
presentation by flow cytometry using antibody that binds specifically to SIINFEKL in context of MHC-I. Graph shows average increase in flow
cytometric mean fluorescence intensity (MFI) representing specific SIINFEKL antigen presentation by mutant DCs relative to normalized values of
control DCs in individual experiments (right bar; *P < 0.05). To the left, bar is shown for response by Sdc4/ mutant DCs relative to control for
comparison (with reference to Figure 1C). (D) Representative flow cytometry histogram showing antigen presentation by SIINFEKL-pulsed Ndst1f/f
CD11cCre+ mutant (right-most curve) versus Ndst1f/f CD11cCre control DCs relative to baseline signal for non-pulsed control cells (left-most curve);
MFI values indicated by bars on (log-scale) fluorescence axis.
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responses when incubated with tumor cells purified from the same respec-
tive mice. Importantly, CD8+ T cells from the spleens of Sdc4/
mutant mice demonstrated greater cytolytic responses against their respec-
tive tumors than that for wildtype mice (Figure 1B). While the Sdc4 muta-
tion is systemic, DCs from the mutant animals are nevertheless deficient inHS (due to loss-of-function mutation in the syndecan-4 HSPG core pro-
tein), prompting us to hypothesize that HS deficiency on these cells might
possibly boost the ability of the mutant DCs to activate anti-tumor T-
cytotoxic responses through either nonspecific or even antigen-specific
mechanisms. Considering the latter, we could test whether the HSPG
(Sdc4) on the DC surface may serve to somehow regulate antigen pre-
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in some way facilitate presentation of antigen in the context of MHC-I.
Indeed, in antigen presentation studies using an antibody that specifically
binds model antigen (the Ova SIINFEKL peptide) in the context of
MHC-I, we noted that DCs purified from Sdc4/ mutant mice and
pulsed with peptide demonstrated a significant (33%) increase in level
of antigen presence (modeling presentation that might be sensed by a
CD8+ T-cell receptor) on the DC surface by flow cytometry (Figure 1C).
With a focus on Ndst1 mutation, in early studies examining Ndst1f/f
LysMCre mutants [12], we previously showed that cells with this mutation
(targeted to a DC-enriched myelomonocytic population) are endowed
with a phenotype characterized by slowed trafficking responses toward
lymphatic chemokines and a cell-surface profile consistent with increased
maturation. However, in vivo, it is unclear whether Ndst1 deficiency in
DCs dominates the anti-tumor response in the Ndst1f/f LysMCre LLC
tumor model, where the effect of mutation on macrophages and granulo-
cytes/neutrophils could theoretically also contribute. More importantly,
beyond an anti-tumor immunophenotype with augmented maturation
of purified DCs from the model, questions as to whether DC-specific
anti-tumor mechanisms are glycan-modulated, their functional nature,
and major downstream CD8+ T-cell responses have not been reported.
To address this, we first restricted the Ndst1 mutation to CD11c
expressing cells in the same in vivo models by generating Ndst1f/f
CD11cCre mutants; and strikingly this resulted in a markedly more pro-
found inhibition in tumor growth (Figure 2A), prompting us to examine
basic DC mechanisms on this genetic background with optimal targeting
of conventional DCs. Initially, we noted marked proliferative effects on
tumor-associated CD8+ T cells: This appeared significant in both the sub-
cutaneous tumor model (with direct measures of CD8+ T cells isolated
from the tumors; Figure 2B) as well as an orthotopic lung model wherein
distal-airway tumor inoculation (established via intra-tracheal LLC deliv-
ery) was associated with increased CD8+ T cells recovered in bronchoalve-
olar lavage (BAL) samples at time of experiment termination (Figure 2D).
Tumor exposure in the latter model was limited to one week so as to acti-
vate an anti-tumor immunologic response toward the airway side of the
alveolar-capillary barrier of the lung (rather than invasion of tumor deep
into the lung parenchyma which might be achieved in longer-term mod-
els), hence driving lung CD8+ T cells toward the airway-inoculated tumor
cells; and assayed/retrieved via BAL at termination of the short-term expo-
sure. This served as an immunologic proof-of-concept to elicit lung T-cell
responses in a short-term airway exposure model with LLC tumor cells. As
a clinical extension, it is compelling to consider how DC-targeted Ndst1
inhibition in human adenocarcinoma-in-situ (a common form of adeno-
carcinoma that spreads along airways and does not invade the alveolar
epithelial basement membrane) might augment anti-tumor CD8+ T cell
responses, and possibly inhibit growth and ultimate progressive basement
membrane invasion by such tumors.
While proliferation of anti-tumor specific CD8+ T cells in vivo might
result from hyper-mature DCs induced by this mutation (Figure 3C), it is
also likely that an increase in antigen-driven specific functional T cell
responses by the DC mutation serves to drive proliferative expansion of
the anti-tumor CD8+ T cell population [9]. Since anti-tumor immunity
during the 2-week model tumor growth period (referring to model in Fig-
ure 2A) may ultimately result in the ability of CD8+ T-splenocytes to
exert an cytotoxic anti-tumor responses, the effect of a conventional
DC-targeted Ndst1 mutation (via the CD11cCre transgenic approach)
on CD8+ T cell mediated cellular immunity was examined: We specifi-
cally examined how effectively CD8+ T cells pooled and purified from
the spleens of tumor-bearing animals might lyse pooled tumor cells from
the same animals in cytolytic effector:target studies wherein anti-tumor
cytolytic effects could only be due to the DC-driven alteration in HS.
We found an augmented capacity for cytolysis by such effector T cellsfrom Ndst1f/f CD11cCre+ mutants (Figure 4A) as compared to that of
Cre controls; and while the findings corroborate data in the setting of
Sdc4/ mutation (as in Figure 1B) with partial absence of HS chains
through mutation of a key DC HSPG, we highlight the specificity with
regards to DC targeting in mechanistic studies using CD8+ T cells from
Ndst1f/f CD11cCre mutants.
In further functional studies, augmented anti-tumor cytolytic effects by
CD8+ T cells purified directly from tumors (reflecting the tumor-
infiltrating ``TIL'' cells) on the Ndst1f/f CD11cCre+ mutant background
(Figure 4B, as compared to that of Cre controls) were paralleled by fur-
ther mechanistic studies demonstrating an even greater effect of Ndst1
mutation in augmenting SIINFEKL/MHC-I antigen presentation by
purified DCs (Figure 4C, right bar with > 2-fold effect over control) when
comparing to that achieved by Sdc4/ mutant DCs (Figure 4C, left bar
with  30% increase over control). The latter may be due to the fact that
while the Ndst1f/f CD11cCre+ mutation is partial (Ndst1 deletion effi-
ciency in DCs  50–70%), unlike Sdc4/ mutation, glycan under-
sulfation via Ndst1 mutation affects all HSPGs, including Sdc3, Perlecan,
or others (Figure 1G) that could conceivably contribute to antigen/MHC-
I interactions with the TcR, or even the half-life of steric antigen display at
the DC surface. The latter cell-biologic and biochemical mechanisms are
beyond the scope of our functional mechanistic focus herein, but are
worth consideration in future exploratory studies. Figure 5 shows a con-
ceptual illustration indicating possible roles for HS chains tethered to
HSPG core proteins on the DC surface, focused on regulatory interactions
with antigen/MHC-I (where mutation or under-sulfation might augment
antigen presentation for example) and/or other effects that directly or indi-
rectly regulate maturation and DC functional outcomes when glycans are
genetically targeted or modulated through other means.
The cytolytic studies herein provide a compelling mechanistic clue that
this may be due to the anti-tumor immunologic effects of altering glycans
on the surface of conventional DCs in the mouse models. Whether Sdc4
deficiency on the surface of T cells in Sdc4/ mutants has additional
effects is unknown; but it is curious that recent work has shown that
Sdc4 on T cells may play a co-inhibitory role at the immune synapse
through a T-cell inhibitory interaction with the DC (and myelomono-
cytic) ligand DC-HIL [25,26]. Thus, interference with Sdc4 (and possibly
HS) expression may serve to increase CD8+ T cell immunity through
novel mechanisms of increased antigen presentation proposed herein
(i.e., referring to proof-of-principle as in Figure 4C), and possibly addi-
tionally through less ``antigen-specific'' immune-checkpoint pathways
that may repress CD8+ T cell functions at baseline through expression
of Sdc4 and/or HS on other proteoglycans. Interrogating these alternate
systems may be helpful in the context of further therapeutic discovery
studies, but lies beyond the scope of this work.
At a biochemical targeting level, as introduced above, the ability to
achieve marked reductions in Ndst1 was somewhat limited by the deletion
efficiency of CD11cCre in tumor-derived DCs, lung-derived DCs (Fig-
ure 1E), and/or BMDCs (Figure 3A). Nevertheless, a strength is that
we were able to confirm the effects of this degree of deletion efficiency
on glycan composition through HS purification from mutant and wild-
type BMDCs, followed by disaccharide analysis of HS disaccharide sulfa-
tion profiles by LC/MS. We believe that the HS composition analysis
reflects that of predominantly BMDCs in the DC-enriched cultured mar-
row preparations. Macrophages in the GM-CSF differentiated marrow
culture made up only a minority of the overall cell population (Figure 1F,
upper right quadrants). Moreover, in a study by Gordts and colleagues
examining HS compositional analysis of macrophages [27], including
under Ndst1 targeting, Ndst1 mutation resulted in a very minimal
(<10%) reduction in sulfation of HS (including the dominant tri-
sulfated disaccharide species) from marrow-derived macrophages. In
another study (not focused on targeting HS), the relative quantity of
Figure 5. Model of DC – T cell interactions that may boost specific anti-tumor immunity in the setting of a targeted alteration in DC cell-surface HS
glycan chains. Antigen presentation during a DC – T cell interaction is shown in the setting of HS proteoglycans with possible regulatory roles by HS
chains. The DC (bottom) shows DC membrane with MHC-I (including b2-microglobulin, which is known to bind HS) and a bound antigen (Ag;
which may represent a tumor antigen) interacting with a CD8+ T-cell receptor (TcR; top), wherein optimal presentation of Ag on MHC-I promotes TcR
signal activation as well as T-cell proliferation. The possibility of control/internalization of Ag/MHC-I cell-surface complex on the DC surface (cell-
inward curved arrow) by cell-surface HS proteoglycans (HSPGs; in pink with red HS chains) is illustrated. Altering HS chain sulfation may ``de-regulate''
and enhance quality and timing of the interaction. In addition, binding of toll-like-receptor (TLR) ligands (Lig) such as LPS to cognate receptors on the
DC may also stimulate DC maturation: This may also be regulated by HS; and represented conceptually in diagram. Possible net effects of a DC-targeted
HS chain mutation (i.e., under-sulfation through Ndst1 deficiency) may thus include: augmented quality of the Ag/MHC-I – TcR interaction, extended
Ag presentation as a result of inhibited Ag/MHC-I internalization by HSPGs, and/or augmented TLR maturation responses.
96 Functional Cellular Anti-Tumor Mechanisms are Augmented P. Gupta et al. Neoplasia Vol. 22, No. 2, 2020the unique tri-sulfated HS disaccharide species (in both M1 and M2
monocyte-derived macrophages) was much more modest relative to that
of other disaccharides [28]. With these data in mind, and with the minor
contribution by macrophages in our preparations, we postulate that the
marked difference in sulfated disaccharides between Ndst1-mutant and
wildtype marrow-differentiated DC-enriched myeloid cells in our study
must be due to major composition differences in a dominant DC popula-
tion (including that of the dominant tri-sulfated disaccharide species).
While reductions in N-sulfation were achieved in mono-, di-, and
trisulfated HS disaccharides, there were also reductions in 2-O-sulfation
and 6-O-sulfation among the di- and tri-sulfated species: sulfation of these
depends to some degree on N-sulfation of nascent HS chains during
biosynthesis. Interestingly, the most abundant species was the most den-
sely sulfated (trisulfated) species making up approximately 40% (molar
%) of all sulfated disaccharides: In HS from Ndst1 mutant DCs, under-
sulfation was associated with approximately 50% reduction in this species
(Figure 3B), indicating the importance of N-sulfation in the biosynthesis
of this heavily sulfated species. It is curious as to why sulfation of HS on
DCs may be so heavily represented by this densely-sulfated disaccharide
(compare to HS composition from mesenchymal/endothelial cells for
example). Whether this is somehow tied to DC immunologic function
and regulatory control of antigen presentation by sulfated glycans is
intriguing.The findings herein have implications with respect to the possibility of
harnessing novel therapeutic pathways to modulate DC function endoge-
nously. The mechanistic findings are in line with goals to improve specific
T-cell mediated anti-tumor immunity in a manner that may be responsive
to a dynamic tumor-antigen landscape with possibilities for novel glycan
targeting to boost antigen-specific CD8+ T cell immunity by endogenous
DCs in the tumor and/or draining lymph nodes.Acknowledgments
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